

AGENDA

Subject to Change

DAY 1 – WEDNESDAY, 10 JUNE 2026

09:00 – 10:30 REGISTRATION & WELCOME NETWORKING

10:30 – 10:35 DCAT WELCOME



Allison Vavala

DCAT Director

Senior Director of Business Development

Flamma Group



Stacey R. Vaughan

Vice President, Marketing & Portfolio Management

West Pharmaceutical Services, Inc.

10:35 – 11:25 **KEYNOTE: SHAPING THE FUTURE: DIGITAL TOOLS FOR DURABLE TRANSFORMATION IN BIO/PHARMA**



Dr. Christine Allen

Chief Executive Officer & Co-founder, Intrepid Labs Inc.

and Professor, University of Toronto

Drawing on lessons from integrating AI into established development workflows, Dr. Allen will highlight what makes digital transformation durable: tools designed with domain experts, transparent trade-offs, and human-in-the-loop decision support that strengthens scientific judgment, sharing a practical vision for the future of bio/pharma: a digital-by-design approach to drug development where experiments, decisions, and supply chains are connected through a modern data backbone.

11:25 – 12:15**DIGITAL TRANSFORMATION THAT DELIVERS:
HOW PHARMA LEADERS ARE BUILDING SMARTER, FASTER
& MORE RESILIENT INTERNAL PROCESSES****Thomas Altmann**
Principal Global Technical Consultant
Ecolab Deutschland GmbH**Clemente Aguila**
Head of Operations & Corporate Procurement
Grifols**Moderator: Ken Seufert**
Chief Executive Officer
JRS Pharma, LP

AI and validated digital solutions are reshaping how bio/pharma companies operate, compete, and scale globally. Our experts will share how organizations are modernizing manufacturing, quality and procurement processes to accelerate decision-making, enhance supply continuity, and enable faster execution and measurable business results.

12:15 – 13:00**THE CRITICAL MEDICINES ACT – PERSPECTIVES FROM
EUROPE'S CDMO AND EXCIPIENTS INDUSTRY****Steffen Denzinger, PhD**
President, Board of Directors
European Fine Chemicals Group

Introduced in March 2025, the European Commission's proposed **Critical Medicines Act (CMA)**, is designed to address the profound vulnerabilities in global pharmaceutical supply chains, revealing Europe's heavy reliance on external sources for many essential medicines. Key aspects of the proposal are currently moving through negotiations. As the representative voice of Europe's CDMO and excipient manufacturers, Dr. Stephen Denzinger, will share insights on strategic funding initiatives, supply chain resilience, and creating a future-ready ecosystem with the right policy framework and viable business conditions.

13:00 – 13:50 NETWORKING LUNCHEON – BESO RESTAURANT**13:50 – 14:40 AI-DRIVEN DRUG DEVELOPMENT: ACCELERATING API PROCESS STAGES, FROM ROUTE SCOUTING TO MANUFACTURING****Roman Lagoutte, PhD**
Senior Principal Scientist
Lonza**Anil Kane, PhD**
Global Head of Technical & Scientific Affairs Pharma Services
Thermo Fisher Scientific**Moderator: Michael Semo**
Associate Vice President
Eli Lilly and Company

Discover how AI is transforming drug development from early route design through API manufacturing. Industry leaders will share real-world strategies for using data, machine learning, and advanced process design to reduce timelines, improve scalability, and strengthen supply reliability.

14:40 – 15:40 CASE STUDIES: TECHNOLOGY IN ACTION**Andrew Lewis, PhD**
Chief Scientific Officer
Quotient Sciences**Dr. Christine Allen**
Chief Executive Officer & Co-founder, Intrepid Labs Inc. and Prof. University of Toronto**Yaman Tobaje**
Senior Engineer, MSAT
Made Scientific**Yu-Shun (Leo) Hsiao**
Founder & Chief Executive Officer
Streamline Bio**Timo Liebig, PhD**
Chief Innovation Officer
Mabxience**Félix Fernández Romero**
Director of AI Transformation & Business Development
HP

15:40 – 16:10 **NETWORKING & REFRESHMENTS**

16:10 – 17:00 **TRUST BY DESIGN: APPLYING QUALITY BY DESIGN PRINCIPLES TO TRUSTWORTHY AI****Michael Schorpp**
Head of Digital Innovation & AI, Global Regulatory Affairs
Boehringer Ingelheim

In Retrieval Augmented Generation (RAG) and agentic AI systems, instabilities in embeddings and retrieval can lead to inconsistent answers, hallucinations, and compounding errors, undermining trust and making regulatory acceptance impossible. Through real world examples, our expert will introduce Trust by Design (TbD), a practical framework that adapts proven Quality by Design (QbD) principles from pharmaceutical development (ICH Q8) to AI systems, detailing how AI output quality can be defined, measured, and controlled through concepts familiar to regulators.

17:00 – 17:10 **DAY ONE CLOSING REMARKS**

19:00 – 21:00 **COCKTAIL RECEPTION & DINNER**
Radio Rooftop Bar, ME Sitges Terramar

DAY 2 – THURSDAY, 11 JUNE 2026

08:00 – 09:00 NETWORKING BREAKFAST – BESO RESTAURANT

09:00 – 09:05 DAY TWO OPENING COMMENTS

Tara Wojcik
Business Integration Manager
Global Pharma Accounts
Winpak Ltd.

**09:05 – 09:55 EUROPEAN PHARMA MARKET INTELLIGENCE
& FINANCIAL OUTLOOK**

Graham Lewis
Vice President, Global Pharma Strategy
IQVIA

How are accelerating healthcare pressures and global policy shifts reshaping the bio/pharmaceutical industry, and what does that mean for Europe's future competitiveness? Drawing on latest European market data trends and case examples to examine levers for R&D and commercial success, noted industry veteran, Graham Lewis, shares his views on what it takes to win in Europe as systems face increasing pressure, competition intensifies, and the rules of bio/pharma continue to change.

09:55 – 11:15**BUILDING A RESILIENT PHARMA SUPPLY CHAIN:
STRATEGY, RISK & INNOVATION FOR THE FUTURE****Gijs Vissers**
*Head of Supply
& Procurement*
Nordic Pharma**Jagruti Patel**
*Sr. Director,
Commercial Development*
Integrated Biologics EMEA/AP
Lonza**Priya Kumar**
*Founder &
Chief Executive Officer*
Sustainable Inc.**Abhay Bhutkar**
Director, Strategic Accounts
QYOBO**Moderator: Arul Ramadurai**
Chief Commercial Officer
Axplora

Industry leaders are mitigating risk through smarter partnerships, AI-enabled procurement, data-driven decision-making, and resilient global manufacturing strategies. This fast-paced session, featuring a panel of experts, delivers practical insights to help organizations stay agile, protect supply continuity, and build stronger, future-ready operations in a rapidly shifting global landscape.

11:15 – 11:45**NETWORKING & REFRESHMENTS**

11:45 – 12:45**BEYOND TECHNOLOGY: PREPARING PEOPLE & ORGANIZATIONS FOR THE AI ERA****Sigma Mostafa, PhD**
Chief Scientific Officer
KBI Biopharma**Coral Butler**
Group Head of Digitally Enabled Lean Project Delivery
PM Group**Moderator: Kelsey Achenbach**
Vice President, Pharma
dsm-firmenich

AI is transforming not just technology, but the way organizations learn, decide, and operate. This forward-looking session explores how pharma companies are preparing their people and systems for the future through smarter AI-driven governance, modern digital learning models, and scalable workforce development strategies. Gain practical insights for building agile, future-ready organizations that can thrive in constant change.

12:45 – 13:45**NETWORKING LUNCHEON – BESO RESTAURANT****13:45 – 15:15****WORKSHOP: FROM ZERO TO AI-POWERED WORKFLOWS IN 90 MINUTES****Dr. Ayesha Khanna**
Chief Executive Officer
Addo AI

In this immersive lab, step into the world of AI agents as participants experience how to work with **Claude Cwork** in practice: managing workflows, collaborating through a simulated use case based on a real business problem, and seeing where it adds value. Participants explore the operational and judgemental risks associated with using AI at work.

15:15 – 15:45 NETWORKING & REFRESHMENTS

15:45 – 16:45 CLOSING ROUNDTABLE: INDUSTRY LEADERS UNPLUGGED



Fabrice Cornille, PhD
*Executive Director
Global Business
Flamma SpA*



Aditya Varna Iyer, DPhil
*Chief Executive Officer
Allos AI*



Arul Ramadurai
*Chief Commercial
Officer
Aexplora*



Charles Davies
*Chief Executive Officer
of Global Pharma
BrandNu Labs (a Caldic Company)*



Sigma Mostafa, PhD
*Chief Scientific Officer
KBI Biopharma*



Moderator:
Sucheth Davuluri
*Vice Chairman &
Chief Executive Officer
Neuland Laboratories Ltd.*

An unscripted conversation with C-level executives, focusing on the most urgent industry issues (“What keeps you up at night?”) and real-time strategies for addressing them.

16:45 – 17:00 2026 DCAT GLOBAL SUMMIT CLOSING REMARKS

17:00 – 19:00 DEPARTING COCKTAIL RECEPTION
